Targeting ACBP/DBI to Fight Fatty Liver Disease

Acyl-CoA binding protein (ACBP), also known as diazepam-binding inhibitor (DBI), plays a crucial role in controlling autophagy in our bodies. Research has shown that people with metabolic-associated steatohepatitis (MASH) or liver fibrosis have higher levels of ACBP/DBI in their blood compared to healthy individuals. This increase is linked to scores that measure the severity of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis, regardless of age or weight.

Scientists tested a special antibody that blocks ACBP/DBI in mice with different types of liver disease. These mice were fed special diets or given harmful substances to trigger liver damage. The antibody treatment reduced signs of liver damage, such as fat buildup, inflammation, and scarring. This suggests that ACBP/DBI might be a key factor in MASH and liver fibrosis, and targeting it could be a potential treatment strategy.

Actions